Eli Lilly and Company has made another move in bolstering its presence in genetic diseases by driving a $139m series B financing for Jaguar Gene Therapy and its pipeline that includes potential one-time treatments for type 1 diabetes and autism.
The Illinois-based company only came out of stealth mode at the end of February this year, led by key members...








